Market Closed -
Nasdaq
04:00:00 2024-05-08 pm EDT
|
5-day change
|
1st Jan Change
|
208
USD
|
-4.55%
|
|
-1.21%
|
-10.09%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,406
|
1,719
|
1,449
|
5,179
|
4,568
|
4,434
|
-
|
-
|
Enterprise Value (EV)
1 |
966.7
|
1,436
|
1,179
|
4,869
|
4,051
|
4,340
|
4,550
|
4,178
|
P/E ratio
|
-16.7
x
|
-8.49
x
|
-5.79
x
|
-16.8
x
|
-11.6
x
|
-7.57
x
|
-12.3
x
|
39.1
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
53.6
x
|
12.2
x
|
4.53
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
52.4
x
|
12.6
x
|
4.27
x
|
EV / EBITDA
|
-10.2
x
|
-6.96
x
|
-4.87
x
|
-16.6
x
|
-10.7
x
|
-7.91
x
|
-9.51
x
|
-44.1
x
|
EV / FCF
|
-23.1
x
|
-9.09
x
|
-4.87
x
|
-16.6
x
|
-12.4
x
|
-8.38
x
|
-10.6
x
|
-17.5
x
|
FCF Yield
|
-4.32%
|
-11%
|
-20.6%
|
-6.01%
|
-8.04%
|
-11.9%
|
-9.41%
|
-5.7%
|
Price to Book
|
3.37
x
|
7.18
x
|
7.15
x
|
26.6
x
|
11.3
x
|
-41.7
x
|
-12.8
x
|
33.6
x
|
Nbr of stocks (in thousands)
|
15,429
|
15,466
|
17,097
|
17,842
|
19,743
|
21,312
|
-
|
-
|
Reference price
2 |
91.11
|
111.2
|
84.74
|
290.2
|
231.4
|
208.0
|
208.0
|
208.0
|
Announcement Date
|
2/26/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
82.79
|
362.1
|
977.7
|
EBITDA
1 |
-94.86
|
-206.2
|
-242.1
|
-293.1
|
-380
|
-548.6
|
-478.5
|
-94.64
|
EBIT
1 |
-94.97
|
-206.7
|
-242.5
|
-293.6
|
-380.5
|
-600.8
|
-411.3
|
85.46
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-725.78%
|
-113.59%
|
8.74%
|
Earnings before Tax (EBT)
1 |
-83.95
|
-202.2
|
-241.8
|
-295.4
|
-373.6
|
-582.3
|
-392.4
|
42.63
|
Net income
1 |
-83.95
|
-202.2
|
-241.8
|
-295.4
|
-373.6
|
-565.9
|
-375.9
|
47.18
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-683.62%
|
-103.81%
|
4.83%
|
EPS
2 |
-5.450
|
-13.09
|
-14.63
|
-17.23
|
-19.99
|
-27.49
|
-16.85
|
5.325
|
Free Cash Flow
1 |
-41.8
|
-157.9
|
-242.3
|
-292.5
|
-325.7
|
-517.7
|
-428.2
|
-238.2
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-625.34%
|
-118.25%
|
-24.37%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/26/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
5.346
|
24.28
|
53.31
|
55.88
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-78.21
|
-
|
-
|
-
|
-151.9
|
-138
|
-134.8
|
-124.4
|
-
|
EBIT
1 |
-63.16
|
-64.6
|
-57.59
|
-70.27
|
-80.41
|
-85.3
|
-78.34
|
-86.45
|
-98.53
|
-117.2
|
-152
|
-164.5
|
-155.4
|
-125.8
|
-139.3
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-3,077.75%
|
-640.25%
|
-235.96%
|
-249.34%
|
Earnings before Tax (EBT)
1 |
-63.1
|
-64.55
|
-57.52
|
-70.73
|
-81.2
|
-85.9
|
-76.9
|
-85.8
|
-98.74
|
-112.2
|
-147.5
|
-163.7
|
-152.1
|
-124.3
|
-122.3
|
Net income
1 |
-63.1
|
-64.55
|
-57.52
|
-70.73
|
-81.2
|
-85.9
|
-76.9
|
-85.8
|
-98.74
|
-112.2
|
-147.5
|
-155.5
|
-144.6
|
-122.4
|
-122.3
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-2,908.24%
|
-595.81%
|
-229.62%
|
-218.82%
|
EPS
2 |
-3.790
|
-3.790
|
-3.360
|
-4.140
|
-4.750
|
-4.980
|
-4.230
|
-4.690
|
-5.340
|
-5.680
|
-7.380
|
-7.503
|
-7.006
|
-5.998
|
-6.552
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/4/21
|
2/24/22
|
5/9/22
|
8/4/22
|
11/3/22
|
2/23/23
|
5/9/23
|
8/8/23
|
11/6/23
|
2/28/24
|
5/7/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
116
|
-
|
Net Cash position
1 |
439
|
284
|
270
|
309
|
517
|
93.5
|
-
|
256
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-0.243
x
|
-
|
Free Cash Flow
1 |
-41.8
|
-158
|
-242
|
-293
|
-326
|
-518
|
-428
|
-238
|
ROE (net income / shareholders' equity)
|
-18.8%
|
-61.6%
|
-111%
|
-
|
-124%
|
-105%
|
10.9%
|
-257%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
27.00
|
15.50
|
11.90
|
10.90
|
20.40
|
-4.980
|
-16.30
|
6.200
|
Cash Flow per Share
2 |
-
|
-
|
-
|
-
|
-
|
-17.60
|
-14.00
|
-
|
Capex
1 |
0.17
|
0.33
|
0.21
|
0.22
|
1.48
|
1.74
|
2.32
|
2.16
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
2.1%
|
0.64%
|
0.22%
|
Announcement Date
|
2/26/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/28/24
|
-
|
-
|
-
|
Average target price
371.8
USD Spread / Average Target +78.71% Consensus |
1st Jan change
|
Capi.
|
---|
| -10.09% | 4.64B | | +2.93% | 106B | | +7.02% | 23.47B | | -14.60% | 21.9B | | -7.05% | 18.77B | | -38.55% | 17.85B | | -8.83% | 16.78B | | +5.51% | 14.41B | | +37.49% | 12.86B | | +329.39% | 8.78B |
Bio Therapeutic Drugs
|